Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBIT: 2010-2025

Historic EBIT for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$14.3 million.

  • Northwest Biotherapeutics' EBIT rose 3.25% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2.78%. This contributed to the annual value of -$66.5 million for FY2024, which is 19.82% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' EBIT is -$14.3 million, which was up 3.11% from -$14.8 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' EBIT peaked at -$10.0 million during Q3 2021, and registered a low of -$21.1 million during Q2 2022.
  • Over the past 3 years, Northwest Biotherapeutics' median EBIT value was -$14.8 million (recorded in 2024), while the average stood at -$15.3 million.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' EBIT was 79.01% (2021), while the steepest drop was 149.84% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' EBIT (Quarterly) stood at -$10.7 million in 2021, then crashed by 70.27% to -$18.2 million in 2022, then grew by 16.70% to -$15.1 million in 2023, then fell by 22.17% to -$18.5 million in 2024, then increased by 3.25% to -$14.3 million in 2025.
  • Its EBIT was -$14.3 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$17.3 million in Q1 2025.